A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Clinical Cancer Genetics Bookmark and Share

Clinical Cancer Genetics

 
 
 Mission Statement:
 The City of Hope Division of
 Clinical Cancer Genetics is
 committed to being a national
 leader in the advancement
 of cancer genetics, screening
 and prevention, through
 innovative patient care,
 research and education.
 
 
In light of a growing body of research confirming that many common cancers, including breast, ovarian, and colorectal cancer, are hereditary, the Division of Clinical Cancer Genetics (CCG) Cancer Screening & Prevention Program helps people understand their personal cancer risk profiles, offering a comprehensive cancer risk assessment that takes into account family history and genetics, along with environmental and lifestyle factors. With this information, people can take proactive steps to “outsmart cancer.”
 
 
 
 
The division’s Cancer Genetics Education Program (CGEP) offers courses and professional development tools designed to further health care professionals’ understanding of cancer genetics.
 
 

Major initiatives include:

The Intensive Course (IC) promotes community-based, practitioner-level competence in the selection, application and interpretation of genetic testing in order to provide these critical services in underserved areas.
 
 
 
The Clinical Cancer Genetics Community of Practice (CCGCoP) is a network of clinicians who have graduated from the IC and/or the Cancer Genetics Career Development Program (CGCDP), along with members of the CCGCRN. Those who are part of this unique community have access to collaborators and professional support from other community members, and to enhanced continuing professional development activities offered by CCG.
 
 
 
In the Cancer Genetics Career Development Program, outstanding post-graduate research scientists receive training with a focus on cutting edge genetic and genomic technology. Graduates of this program continue their work in cancer genetics with the goal of reducing the burden of cancer among those at highest risk.
 
 
 
Clinical cancer genetics research at City of Hope investigates multiple approaches that utilize the latest findings in cancer genetics in order to improve the prevention, treatment, and support of those with hereditary cancers.
 
 
 
Major initiatives include:
 
The CCG molecular genetics research laboratory uses a multitude of research tests such as MLPA, long range PCR and next generation sequencing as well as a variety of state of the art equipment to prescreen high risk patients for mutations in cancer predisposition genes such as BRCA1, BRCA2 and RAD51. Specific equipment available in the laboratory include:  -Sequenom MassArray Analyzer (MALDI-TOF Mass spectrometry) -Sequenom MassArray Robotic Nanodispenser -Ion Torrent Personal Genome Machine -Ion One Touch -Nanodrop 2000c spectrophotometer -Qubit 2.0 Fluorometer -ABI 3130xl Genetic Analyzer -Veriti 96 well thermocyclers -Gene Amp 9700 PCR systems
 
 
 
 
An essential but often unmet aspect of providing quality care to persons affected by cancer or those at hereditary cancer risk is addressing their psychosocial needs. As such, understanding and minimizing the negative impact of hereditary cancer risk on persons' lives is the focus of the CCG Clinical and Behavioral Research program. The program studies health-related behaviors, quality of life (including emotional, psychological and basic daily living needs), and ethical, legal, and social issues, by going directly to the source--our patients and their family members.
 
 
 
 
An integral component of the research program is the Cancer Genetics Community Research Network (CCGCRN), a prospective research registry protocol initiated at City of Hope as a biospecimen repository with associated personal and family medical history, and psychosocial and clinical follow-up data collection. Collaborating community-based oncogenetic practice sites across the U.S. and Latin America are recruiting thousands of genetic cancer risk assessment patients annually.
 
 
 
 
 
In addition, CGEP staff participate in educational outreach to medical groups, hospital medical staffs and other community health care professionals. The program is supported in part by the National Cancer Institute and the California Research Program.
 

Clinical Cancer Genetics

Clinical Cancer Genetics

 
 
 Mission Statement:
 The City of Hope Division of
 Clinical Cancer Genetics is
 committed to being a national
 leader in the advancement
 of cancer genetics, screening
 and prevention, through
 innovative patient care,
 research and education.
 
 
In light of a growing body of research confirming that many common cancers, including breast, ovarian, and colorectal cancer, are hereditary, the Division of Clinical Cancer Genetics (CCG) Cancer Screening & Prevention Program helps people understand their personal cancer risk profiles, offering a comprehensive cancer risk assessment that takes into account family history and genetics, along with environmental and lifestyle factors. With this information, people can take proactive steps to “outsmart cancer.”
 
 
 
 
The division’s Cancer Genetics Education Program (CGEP) offers courses and professional development tools designed to further health care professionals’ understanding of cancer genetics.
 
 

Major initiatives include:

The Intensive Course (IC) promotes community-based, practitioner-level competence in the selection, application and interpretation of genetic testing in order to provide these critical services in underserved areas.
 
 
 
The Clinical Cancer Genetics Community of Practice (CCGCoP) is a network of clinicians who have graduated from the IC and/or the Cancer Genetics Career Development Program (CGCDP), along with members of the CCGCRN. Those who are part of this unique community have access to collaborators and professional support from other community members, and to enhanced continuing professional development activities offered by CCG.
 
 
 
In the Cancer Genetics Career Development Program, outstanding post-graduate research scientists receive training with a focus on cutting edge genetic and genomic technology. Graduates of this program continue their work in cancer genetics with the goal of reducing the burden of cancer among those at highest risk.
 
 
 
Clinical cancer genetics research at City of Hope investigates multiple approaches that utilize the latest findings in cancer genetics in order to improve the prevention, treatment, and support of those with hereditary cancers.
 
 
 
Major initiatives include:
 
The CCG molecular genetics research laboratory uses a multitude of research tests such as MLPA, long range PCR and next generation sequencing as well as a variety of state of the art equipment to prescreen high risk patients for mutations in cancer predisposition genes such as BRCA1, BRCA2 and RAD51. Specific equipment available in the laboratory include:  -Sequenom MassArray Analyzer (MALDI-TOF Mass spectrometry) -Sequenom MassArray Robotic Nanodispenser -Ion Torrent Personal Genome Machine -Ion One Touch -Nanodrop 2000c spectrophotometer -Qubit 2.0 Fluorometer -ABI 3130xl Genetic Analyzer -Veriti 96 well thermocyclers -Gene Amp 9700 PCR systems
 
 
 
 
An essential but often unmet aspect of providing quality care to persons affected by cancer or those at hereditary cancer risk is addressing their psychosocial needs. As such, understanding and minimizing the negative impact of hereditary cancer risk on persons' lives is the focus of the CCG Clinical and Behavioral Research program. The program studies health-related behaviors, quality of life (including emotional, psychological and basic daily living needs), and ethical, legal, and social issues, by going directly to the source--our patients and their family members.
 
 
 
 
An integral component of the research program is the Cancer Genetics Community Research Network (CCGCRN), a prospective research registry protocol initiated at City of Hope as a biospecimen repository with associated personal and family medical history, and psychosocial and clinical follow-up data collection. Collaborating community-based oncogenetic practice sites across the U.S. and Latin America are recruiting thousands of genetic cancer risk assessment patients annually.
 
 
 
 
 
In addition, CGEP staff participate in educational outreach to medical groups, hospital medical staffs and other community health care professionals. The program is supported in part by the National Cancer Institute and the California Research Program.
 
Clinical Cancer Genetics
The City of Hope Division of Clinical Cancer Genetics is committed to being a national leader in the advancement of cancer genetics, screening and prevention, through innovative patient care, research and education.

Contact Us
  • 800-826-HOPE (4673)
  • For more information about the Cancer Screening & Prevention Program, call 626-256-8662, ext. 2.
Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
City of Hope Breakthroughs
Get the latest in City of Hope's research, treatment and news you can use on our blog, Breakthroughs.
 
 
NEWS & UPDATES
  • City of Hope is extending the reach of its lifesaving mission well beyond U.S. borders. To that end, three distinguished City of Hope leaders visited China earlier this year to lay the foundation for the institution’s new International Medicine Program. The program is part of City of Hope’s strategi...
  • A hallmark of cancer is that it doesn’t always limit itself to a primary location. It spreads. Breast cancer and lung cancer in particular are prone to spread, or metastasize, to the brain. Often the brain metastasis isn’t discovered until years after the initial diagnosis, just when patients were beginning to ...
  • Blueberries, cinnamon, baikal scullcap, grape seed extract (and grape skin extract), mushrooms, barberry, pomegranates … all contain compounds with the potential to treat, or prevent, cancer. Scientists at City of Hope have found tantalizing evidence of this potential and are determined to explore it to t...
  • Most women who are treated for breast cancer with a mastectomy do not choose to undergo reconstructive surgery. The reasons for this, according to a recent JAMA Surgery study, vary. Nearly half say they do not want any additional surgery, while nearly 34 percent say breast cancer reconstruction simply isn’t imp...
  • The leading risk factor for breast cancer is simply being a woman. The second top risk factor is getting older. Obviously, these two factors cannot be controlled, which is why all women should be aware of their risk and how to minimize those risks. Many risk factors can be mitigated, and simple changes can lead...
  • All women are at some risk of developing the disease in their lifetimes, but breast cancer, like other cancers, has a disproportionate effect on minorities. Although white women have the highest incidence of breast cancer, African-American women have the highest breast cancer death rates of all racial and ethni...
  • First, the good news: HIV infections have dropped dramatically over the past 30 years. Doctors, researchers and health officials have made great strides in preventing and treating the disease, turning what was once a death sentence into, for some, a chronic condition. Now, the reality check: HIV is still a worl...
  • Screening for breast cancer has dramatically increased the number of cancers found before they cause symptoms – catching the disease when it is most treatable and curable. Mammograms, however, are not infallible. It’s important to conduct self-exams, and know the signs and symptoms that should be checked by a h...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free.   In his previ...
  • In a single day, former professional triathlete Lisa Birk learned she couldn’t have children and that she had breast cancer. “Where do you go from there?” she asks. For Birk, who swims three miles, runs 10 miles and cycles every day, the answer  ultimately was a decision to take control of her cancer care. Afte...
  • More and more people are surviving cancer, thanks to advanced cancer treatments and screening tools. Today there are nearly 14.5 million cancer survivors in the United States. But in up to 20 percent of cancer patients, the disease ultimately spreads to their brain. Each year, nearly 170,000 new cases of brain ...
  • Cancer cells are masters of survival. Despite excessive damage to their most basic workings and the constant vigilance of the body’s immune system, they manage to persevere. Much of this extraordinary ability to survive falls under the control of proteins bearing the name STAT, short for signal transducer and a...
  • One person receives the breast cancer diagnosis, but the cancer affects the entire family. Couples, in particular, can find the diagnosis and treatment challenging, especially if they have traditional male/female communication styles. “Though every individual is unique, men and women often respond differently d...
  • Here’s a statistic you’ll hear and read frequently over the next month: One in eight women born in the United States will develop breast cancer at some point in her lifetime. Although this statement is accurate, based on breast cancer incidence rates in 2013, it’s often misunderstood. Leslie Bernstein, Ph.D., d...
  • This time of year, how can anyone not think pink? Through the power of pastel packaging, October has been etched permanently into the American public’s consciousness as Breast Cancer Awareness Month. The color pink is now synonymous with breast cancer. Suffice to say, awareness has been raised. Now itR...